AI주식인사이트AI Stock Insight
B

유나이티드제약

033270KOSPI의약품 제조업

68.0 / 100

Reference Date: 2026-04-13

Financial Score29.5 / 40
News Sentiment17.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

United Pharmaceutical is a specialized generic drug manufacturer focusing on improved drugs, achieving sales of 2.887 trillion won in 2024 with a 20% operating profit margin through key products like Silostan CR Tablets and Artmax Combi Gel. The company maintains advanced production facilities and R&D capabilities, exporting pharmaceuticals to over 40 countries and launching 17 improved drug formulations.

Number of Employees

902people

Average Salary

67.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
7.79Industry Average 14.806.5Point

Lower than industry avg (good)

PBR
0.71Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
8.90Industry Average 4.427.0Point

2.0x industry avg (excellent)

Debt Ratio
3.76Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲1.8% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼4.7% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 10.2% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 1Neutral 2Negative 1Average Sentiment Score 75

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 20,350Won52-week high 22,35052-week low 18,130
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

17 totalPositive 0Neutral 17Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-10
  • Neutral최대주주등소유주식변동신고서2026-04-10
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
  • Neutral최대주주등소유주식변동신고서2026-04-08
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08